|
|
To RxLink FROM: ETHEX CORPORATION
June 2003
To RxLink From: ETHEX, the
nation's leading provider of prescription prenatal vitamins*, is
pleased to provide the enclosed prenatal vitamin reference materials,
designed to help you determine which ETHEX prenatal vitamin to use.
Remove the
ETHEX Born to Lead cross-reference static cling sheet from the paper
backing and post it on any surface in your pharmacy. Consult the
ingredient comparison chart whenever there are questions about the
active ingredients in any ETHEX prenatal vitamin.
To
automatically receive updated reference materials whenever there are
changes to ETHEX's prenatal vitamin family, contact ETHEX by phone at
1-800-321-1705 or by email at info@ethex.com.
Thank you for
dispensing ETHEX prenatal vitamins!
Sincerely,
Brook Eiler
Product Manager
*IMS
America, Units MAT, February 2003.
|
|
As a
demonstration of our ongoing commitment to excellence in customer
service, Apotex Corp. is pleased to announce that Capital Returns has
been selected as our return goods processing agent. Effective
July 1, 2004
all
Apotex Corp. returns for expired and short-dated product should be
sent to Capital Returns, Inc at the following address:
All returns
will be processed in accordance with updated Apotex Corp's Return
Goods Policy, Our
updated policy can be found here. Please review the policy in
detail and update your records accordingly as changes have been made.
Capital
Return's Customer Service Team is available for any questions that
you may have on how to return the product. In
ordeer to avoid any delays in the processing of your returns, please
make sure to include the following information with your return: your
complete company name and address, your wholesaler name and address
(if applicable), debit memo number and current DEA number and
expiration date.
Should you
have any questions regarding the status of a return, please call
Capital Returns, Inc at 800-950-5479.
Thank you for
your valued business.
Source: Apotex Corp |
From: GlaxoSmithKline
August 2007
Important
Prescribing Information
GlaxoSmithKline
(GSK) is fully committed to the timely communication of safety
information about its products to the healthcare community. In
collaboration with the U.S. Food and Drug Administration, we are
updating the rosiglitazone prescribing information with regard to
heart failure. This labeling affects rosiglitazone-containing
products, i.e. Avandia® (rosiglitazone maleate) tablets,
Avandamet (rosiglitazone maleate and metformin hydrocloride) tablets,
and Avandaryl (rosiglitazone maleate and glimeperide) Tablets, which
are used in treating type 2 diabetes melitus.
Important
changes to the Prescribing Information for Avandia, Avandamet and
Avandaryl include:
1. Boxed
warning regarding heart failure...
2.
Contraindication for initiation of rosiglitazone in patients with
NYHA class III and IV heart failure.
WARNING: CONGESTIVE HEART FAILURE
.
Thiazolidinediones, including rosiglitazone, cuase or exacerbate
congestive heart failure in some patients. After initiation of
Avandia, and after dose increases, observe patients carefully for
signs and symptoms of heart failure (including excessive, rapid
weight gain, dyspnea, and / or edema). If these symptoms
develop, the heart failure should be managed according to current
standards of care. Futhermore, discontinuation or dose
reduction of AVANDIA must be considered.
. AVANDIA is
not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with establised NYHA Class III or
Class IV heart failure is contraindicated.
|
|
